Cite
Chipps BE, Albers FC, Reilly L, et al. Efficacy and safety of as-needed albuterol/budesonide versus albuterol in adults and children aged ≥4 years with moderate-to-severe asthma: rationale and design of the randomised, double-blind, active-controlled MANDALA study. BMJ Open Respir Res. 2021;8(1)doi: 10.1136/bmjresp-2021-001077.
Chipps, B. E., Albers, F. C., Reilly, L., Johnsson, E., Cappelletti, C., & Papi, A. (2021). Efficacy and safety of as-needed albuterol/budesonide versus albuterol in adults and children aged ≥4 years with moderate-to-severe asthma: rationale and design of the randomised, double-blind, active-controlled MANDALA study. BMJ open respiratory research, 8(1), . https://doi.org/10.1136/bmjresp-2021-001077
Chipps, Bradley E, et al. "Efficacy and safety of as-needed albuterol/budesonide versus albuterol in adults and children aged ≥4 years with moderate-to-severe asthma: rationale and design of the randomised, double-blind, active-controlled MANDALA study." BMJ open respiratory research vol. 8,1 (2021). doi: https://doi.org/10.1136/bmjresp-2021-001077
Chipps BE, Albers FC, Reilly L, Johnsson E, Cappelletti C, Papi A. Efficacy and safety of as-needed albuterol/budesonide versus albuterol in adults and children aged ≥4 years with moderate-to-severe asthma: rationale and design of the randomised, double-blind, active-controlled MANDALA study. BMJ Open Respir Res. 2021 Dec;8(1). doi: 10.1136/bmjresp-2021-001077. PMID: 34887317.
Copy
Download .nbib